Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Respiratory Syncytial Virus, Human Metapneumovirus
Interventions: mRNA-1345, mRNA-1365, Placebo, Nimenrix; Biological · Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 5 Months to 24 Months
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Activin ligand-trap biological therapy, Placebo, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more

Conditions: Nausea, Vomiting
Interventions: Alcohol prep pad group, Normal Saline prep pad; Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions: DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 5 Days
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hysterectomy, Blood Loss, Surgical
Interventions: Tranexamic Acid, Sodium Chloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pregnancy, Cesarean Section, Aspiration
Interventions: Study drug metoclopramide, Study drug placebo administration; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Post-operative Craniotomy Patients, Carotid Endarterectomy and Carotid Artery Stenosis Patients, Post-op Spine Patients Admitted to the NCCU, Endovascular Patients Undergoing Intracranial Intervention, Traumatic Brain Injuries NPO for at Least 12 Hours
Interventions: Intravenous acetaminophen, Placebo for IV acetaminophen; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Candidiasis
Interventions: fluconazole, placebo; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 2 Days to 5 Days
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 33
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Obesity, Cardiovascular Physiological Phenomena, Metabolism
Interventions: recombinant human BNP(1-32), placebo (control, normal saline); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Esophageal Spasm
Interventions: Magnesium sulfate, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PRM-151, Placebo; Biological · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Clostridium Difficile Infection
Interventions: SER-109, Placebo; Biological · Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 51
States / cities: North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more

Conditions: Chronic Stable Heart Failure
Interventions: CLR325, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Chicago, Illinois • St Louis, Missouri • Cleveland, Ohio + 3 more

Conditions: Healthy Volunteers
Interventions: Human butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Delayed Function of Renal Transplant
Interventions: SANGUINATE, Normal Saline; Drug
Lead sponsor: Prolong Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 15 more

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions: Meperidine, Midazolam, Diphenhydramine, Promethazine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Alteplase, Unfractionated heparin, Placebo, Apixaban; Drug
Lead sponsor: Victor Tapson, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postoperative Pain
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: ACE-083, ACE-083 or placebo; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions: Caffeine Citrate, Placebo (Normal Saline); Drug
Lead sponsor: Jennifer Shepherd; Other
Eligibility: Up to 1 Day
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Pain, Acute Postoperative, Renal Stone
Interventions: Active bupivacaine 0.25% via an erector spinae plane perineural catheter, Placebo normal saline via an erector spinae plane perineural catheter; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: San Diego, California

Conditions: Acute Pain, Hyperalgesia
Interventions: IV acetaminophen, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Inhalation Intervention for Nausea in the Emergency Department

Pentavalent DTaP-Hep B-IPV

IV Tranexamic Acid Prior to Hysterectomy

Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide

Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Metabolic Effects of Natriuretic Peptide Hormones

Magnesium for Peroral Endoscopic Myotomy

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

A Study of CLR325 in Chronic Stable Heart Failure Patients.

A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Early Caffeine in Preterm Neonates

Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy

IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery